Alessandro Mazzetti

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne

Adelaide A. Hebert, Diane Thiboutot, Linda Stein Gold et al. · JAMA Dermatology · 2020 · 133 citations · Full text

Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris

Lawrence F. Eichenfield, Adelaide A. Hebert, Linda Stein Gold et al. · Journal of the American Academy of Dermatology · 2020 · 45 citations · Full text

Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study

Alessandro Mazzetti, Luigi Moro, Mara Gerloni et al. · PubMed · 2019 · 42 citations

Androgen Receptor, Adrenal Gland, Pharmacokinetic Profile +13

Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro

Caridad Rosette, Frances J. Agan, Alessandro Mazzetti et al. · PubMed · 2019 · 36 citations

Androgen Receptor, Immunology, Pharmacotherapy +18

A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne

Alessandro Mazzetti, Luigi Moro, Mara Gerloni et al. · PubMed · 2019 · 25 citations

Atopic Dermatitis, Phase 2B, Facial Acne +12